FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
Feature|Articles|September 25, 2026
Oral L-Glutamine Could Be Pancreatic Cancer's Most Accessible Treatment Advance: Q&A with Dr. Jun Gong, MD
Author(s)Jun Gong, MD
Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.
Advertisement
Advertisement
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with Pharmaceutical Executive about the results of a Phase I study that researched the impact of adding oral L-glutamine to first-line gemcitabine/nab-paclitaxel in treatment-naïve advanced pancreatic cancer.
Related to this article
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Advertisement
Advertisement